NO20032542L - Dempede anti-CD28-antistoffer og anvendelse derav - Google Patents

Dempede anti-CD28-antistoffer og anvendelse derav

Info

Publication number
NO20032542L
NO20032542L NO20032542A NO20032542A NO20032542L NO 20032542 L NO20032542 L NO 20032542L NO 20032542 A NO20032542 A NO 20032542A NO 20032542 A NO20032542 A NO 20032542A NO 20032542 L NO20032542 L NO 20032542L
Authority
NO
Norway
Prior art keywords
antibodies
attenuated anti
attenuated
Prior art date
Application number
NO20032542A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032542D0 (no
Inventor
J Yun Tso
Paul Hinton
Maximiliano Vasquez
Kouichi Tamura
Yasuyuki Higashi
Nobuo Seki
Hirotsugu Ueda
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20032542D0 publication Critical patent/NO20032542D0/no
Publication of NO20032542L publication Critical patent/NO20032542L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20032542A 2000-12-14 2003-06-05 Dempede anti-CD28-antistoffer og anvendelse derav NO20032542L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (2)

Publication Number Publication Date
NO20032542D0 NO20032542D0 (no) 2003-06-05
NO20032542L true NO20032542L (no) 2003-08-07

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032542A NO20032542L (no) 2000-12-14 2003-06-05 Dempede anti-CD28-antistoffer og anvendelse derav

Country Status (18)

Country Link
EP (1) EP1341553A4 (es)
JP (1) JP2004515243A (es)
KR (1) KR20040020866A (es)
CN (1) CN1272345C (es)
AR (1) AR031924A1 (es)
AU (2) AU2002226086C1 (es)
BR (1) BR0116686A (es)
CA (1) CA2432736A1 (es)
CZ (1) CZ20031909A3 (es)
HU (1) HUP0400697A3 (es)
IL (1) IL156262A0 (es)
MX (1) MXPA03005327A (es)
NO (1) NO20032542L (es)
NZ (1) NZ526569A (es)
PL (1) PL363239A1 (es)
RU (1) RU2261723C2 (es)
WO (1) WO2002047721A1 (es)
ZA (1) ZA200305384B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
HUE039677T2 (hu) * 2010-02-18 2019-01-28 Ose Immunotherapeutics Humanizált anti-CD28-ellenanyagok
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CA3130348A1 (en) * 2019-03-14 2020-09-17 Motti HAKIM A method for immunosuppression
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Also Published As

Publication number Publication date
EP1341553A1 (en) 2003-09-10
PL363239A1 (en) 2004-11-15
HUP0400697A2 (hu) 2004-06-28
CN1272345C (zh) 2006-08-30
CA2432736A1 (en) 2002-06-20
MXPA03005327A (es) 2004-12-03
RU2003121231A (ru) 2005-02-10
JP2004515243A (ja) 2004-05-27
AR031924A1 (es) 2003-10-08
KR20040020866A (ko) 2004-03-09
CZ20031909A3 (cs) 2003-11-12
RU2261723C2 (ru) 2005-10-10
EP1341553A4 (en) 2004-07-28
CN1489473A (zh) 2004-04-14
NZ526569A (en) 2005-07-29
AU2608602A (en) 2002-06-24
AU2002226086C1 (en) 2006-03-09
WO2002047721A1 (en) 2002-06-20
NO20032542D0 (no) 2003-06-05
IL156262A0 (en) 2004-01-04
AU2002226086B2 (en) 2005-08-25
BR0116686A (pt) 2003-12-30
ZA200305384B (en) 2004-10-11
HUP0400697A3 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
NO20034405L (no) Anti-ostepontin-antistoff og anvendelse derav
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
DK1691837T3 (da) IP-10-antistoffer og anvendelse heraf
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20030614L (no) Anti-IL-12-antistoffer, sammensetninger, fremgangsmåter og anvendelser
IS7041A (is) 5-HT viðtakabindlar og notkun þeirra
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
TWI316088B (en) Anti-tnf alpha antibodies and their uses
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
NO20033418L (no) Immunregulatoriske antistoffer og anvendelse derav
IS6411A (is) Kaspasa tálmar og notkun þeirra
NO20033456L (no) Modifiserte og stabiliserte GDF-propeptider og anvendelse derav
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1278763T3 (da) 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil
DK1339292T3 (da) Sammensætning og fremgangsmåde
NO20032542D0 (no) Dempede anti-CD28-antistoffer og anvendelse derav
DK1322597T3 (da) Fremgangsmåde og intermediære
FI20000432A (fi) Putkiliitos
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
DK1317478T3 (da) Skelnen mellem GnRH-I og GnRH-II
IS6570A (is) Þrýstingslækkandi miðlar og notkun
FI20000433A0 (fi) Putkiliitos

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

FC2A Withdrawal, rejection or dismissal of laid open patent application